Targin New Zealand - English - Medsafe (Medicines Safety Authority)

targin

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg; oxycodone hydrochloride 20mg;   - modified release tablet - 20/10mg - active: naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg oxycodone hydrochloride 20mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry pink 85f24151 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

TARGIN® Prolonged Release Tablets 20mg 10mg Singapore - English - HSA (Health Sciences Authority)

targin® prolonged release tablets 20mg 10mg

mundipharma pharmaceuticals pte. ltd. - naloxone 9.00mg eqv naloxone hydrochloride anhydrous; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 10.00 mg/tablet - naloxone 9.00mg eqv naloxone hydrochloride anhydrous 10 mg; oxycodone 18.00mg eqv oxycodone hydrochloride anhydrous 20 mg

TARGIN® Prolonged Release Tablets 40mg 20mg Singapore - English - HSA (Health Sciences Authority)

targin® prolonged release tablets 40mg 20mg

mundipharma pharmaceuticals pte. ltd. - naloxone 18.00mg eqv naloxone hydrochloride anhydrous; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 20.00 mg/tablet - naloxone 18.00mg eqv naloxone hydrochloride anhydrous 20 mg; oxycodone 36.00mg eqv oxycodone hydrochloride anhydrous 40 mg

TARGIN® Prolonged Release Tablets 10mg5mg Singapore - English - HSA (Health Sciences Authority)

targin® prolonged release tablets 10mg5mg

dksh singapore pte. ltd. - naloxone 4.50mg eqv to naloxone hydrochloride anhydrous; oxycodone 9.00mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 5.00 mg/tablet - naloxone 4.50mg eqv to naloxone hydrochloride anhydrous 5 mg; oxycodone 9.00mg eqv oxycodone hydrochloride anhydrous 10 mg

TARGIN® Prolonged Release Tablets 5mg2.5mg Singapore - English - HSA (Health Sciences Authority)

targin® prolonged release tablets 5mg2.5mg

dksh singapore pte. ltd. - naloxone 2.25mg eqv naloxone hydrochloride anhydrous; oxycodone 4.50mg eqv oxycodone hydrochloride anhydrous - tablet, film coated, extended release - 2.50 mg/tablet - naloxone 2.25mg eqv naloxone hydrochloride anhydrous 2.5 mg; oxycodone 4.50mg eqv oxycodone hydrochloride anhydrous 5 mg

TARGIN oxycodone hydrochloride / naloxone hydrochloride 20/10 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

targin oxycodone hydrochloride / naloxone hydrochloride 20/10 mg modified release tablets blister pack

mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 10.9 mg (equivalent: naloxone hydrochloride?, qty 10 mg); oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: magnesium stearate; povidone; macrogol 3350; stearyl alcohol; titanium dioxide; lactose monohydrate; purified talc; polyvinyl alcohol; iron oxide red; ethylcellulose - targin modified release tablet is indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and,- requires daily, continuous, long term treatment.,targin modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,targin modified release tablet is not indicated as an as-needed (prn) analgesia,the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,targin is indicated as a second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Aristiga 20 mg/10mg prolonged release tablet Ireland - English - HPRA (Health Products Regulatory Authority)

aristiga 20 mg/10mg prolonged release tablet

ethypharm - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 20 mg / 10 milligram(s) - natural opium alkaloids; oxycodone, combinations

Aristiga 10 mg/5 mg prolonged release tablet Ireland - English - HPRA (Health Products Regulatory Authority)

aristiga 10 mg/5 mg prolonged release tablet

ethypharm - naloxone hydrochloride; oxycodone hydrochloride - prolonged-release tablet - 10 mg / 5 milligram(s) - natural opium alkaloids; oxycodone, combinations

Oxyargin 10 mg/5 mg prolonged release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

oxyargin 10 mg/5 mg prolonged release tablets

generics (uk) limited - oxycodone hydrochloride; naloxone hydrochloride - prolonged-release tablet - 10 / 5 milligram(s) - natural opium alkaloids; oxycodone, combinations

Targin 10mg/5mg prolonged-release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

targin 10mg/5mg prolonged-release tablets

mundipharma pharmaceuticals limited - oxycodone hydrochloride; naloxone hydrochloride dihydrate - prolonged-release tablet - 10 mg/5 milligram(s) - natural opium alkaloids; oxycodone, combinations